These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15889977)

  • 1. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
    Coca SG; Perazella MA
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].
    Bertocchio JP; Jaisser F
    Nephrol Ther; 2011 Jun; 7(3):139-47. PubMed ID: 21144811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.
    Del Vecchio L; Procaccio M; Viganò S; Cusi D
    Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonism in chronic kidney disease.
    Ponda MP; Hostetter TH
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):668-77. PubMed ID: 17699271
    [No Abstract]   [Full Text] [Related]  

  • 6. [Aldosterone and kidney damage: clinical implications].
    Del Vecchio L; Sitia S
    G Ital Nefrol; 2009; 26(3):347-54. PubMed ID: 19554532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
    Fiebeler A; Luft FC
    Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
    [No Abstract]   [Full Text] [Related]  

  • 8. Aldosterone and progression of kidney disease.
    Cortinovis M; Perico N; Cattaneo D; Remuzzi G
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurohormones and heart failure: the importance of aldosterone.
    Odedra K; Ferro A
    Int J Clin Pract; 2006 Jul; 60(7):835-46. PubMed ID: 16846401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone and cardiovascular disease: smoke and fire.
    Calhoun DA
    Circulation; 2006 Dec; 114(24):2572-4. PubMed ID: 17159070
    [No Abstract]   [Full Text] [Related]  

  • 12. The cardiovascular implications of hypokalemia.
    Coca SG; Perazella MA; Buller GK
    Am J Kidney Dis; 2005 Feb; 45(2):233-47. PubMed ID: 15685500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone and cardiovascular pathology: from bench to bedside.
    Vintilă M; Băluţă M
    Rom J Intern Med; 2004; 42(1):15-26. PubMed ID: 15529592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aldosterone blockade in essential hypertension].
    Venco A; Grandi AM
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
    Cohn JN; Colucci W
    Am J Cardiol; 2006 May; 97(10A):4F-12F. PubMed ID: 16698330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D; Krzesinski JM; Scheen AJ
    Rev Med Suisse; 2008 Aug; 4(168):1792-7. PubMed ID: 18814762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.